Innovation Fertility Partners with Alife Health to Bring AI to IVF Clinics Around the Country
The leading network of fertility clinics joins forces with Alife Health to improve patient care and treatment outcomes
SAN FRANCISCO, March 16, 2023 /PRNewswire-PRWeb/ -- Innovation Fertility, a group of in-vitro fertilization (IVF) clinics and laboratories, and Alife Health, a fertility technology company, today announced their partnership to introduce new artificial intelligence (AI) and advanced analytics technology to the Innovation Fertility network. This collaboration will provide Innovation Fertility clinics with the latest in AI-powered analytics tools so they can make the most informed decisions about patient care.
Innovation Fertility is led by an expert team of fertility professionals that boast decades of experience in laboratory design, advanced technology implementation, and strategic planning to build successful fertility practices.
"Our leadership team has always been driven to discover the most cutting-edge, science-backed technologies in our field," says Dr. Kathleen Miller, Chief Science Officer at Innovation Fertility. "If we want to provide the best possible care to our patients, we know we need to leverage the potential that modern technology offers. Alife has worked hand-in-hand with us to build products that will not only help our clinics work more efficiently and effectively, but will also help us to build more personalized treatment plans for our patients."
Alife Health was founded in 2020 by a team of data scientists, product engineers, and software designers to build a modern operating system for IVF, powered by artificial intelligence. After two years of scientific research and product development, the company officially launched their first product, Alife Assist™, last fall at the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo. A first-of-its-kind software platform, Alife Assist™ utilizes data-driven insights and AI to optimize and support clinical decision-making during critical stages of the IVF process, as well as streamline overall clinic operations.
"We're thrilled to be working with Innovation Fertility to introduce new technologies that will push the field forward and help clinics in their effort to give more patients successful outcomes," says Alife CEO and Founder, Paxton Maeder-York. "Alife's AI and advanced analytics technology provides IVF clinicians with personalized patient insights and predictions drawn from thousands of previous patient cycles from across the country. With this information, clinicians can craft individualized data-driven treatment recommendations to provide their patients optimal care and increase their chances of having a baby."
This partnership is yet another example of how innovation is transforming the field of assisted reproduction - making it easier for couples struggling with infertility to achieve their dreams of becoming parents.
About Alife Health
Alife's mission is to personalize and modernize the IVF process with cutting edge artificial intelligence technology to improve outcomes and care for all. The company has built a consortium of partnerships with the top clinics and most renowned physicians to bring significant clinical improvements to patients globally. Founded by Paxton Maeder-York in 2020, the company is based in San Francisco and backed by top tier venture capital investors including Lux Capital, Union Square Ventures, and Maveron. To learn more visit http://www.alifehealth.com.
About Innovation Fertility
Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine premier reproductive endocrinologists with laboratory operations, resulting in exceptional medical care and an unparalleled patient experience. To learn more visit http://www.iffertility.com.
Media Contact
Jamie Gray, Alife Health, 1 310-699-3163, [email protected]
Dwight Ryan, Innovation Fertility, 914-924-1426, [email protected]
SOURCE Alife Health
![](https://rt.prnewswire.com/rt.gif?NewsItemId=UN43971&Transmission_Id=202303160700PR_NEWS_USPR_____UN43971&DateId=20230316)
Share this article